
Peptides for Men Over 50: What Men Use, What’s Proven, and What It Costs
REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn
Every number links to its study · Published: 2026-08-17 · Last updated: 2026-09-21
Men over 50 buy peptides for six things: holding onto muscle, losing belly fat, getting joints to heal, keeping testosterone and sex drive up, having more energy, and looking less tired in the mirror. This page goes through the sixteen compounds men in that age group actually use, goal by goal, and says which ones have been tested in men your age. Short version: one is an approved drug for a closely related use (tesamorelin), a handful have real human trials (retatrutide, kisspeptin, PT-141, sermorelin, thymosin alpha-1), and the rest are running on animal data and small pilots. Nothing here is approved for anti-aging. Single-compound vials run $29.95 to $69.99 at list; the blends $89.99 to $149.99.
Key takeaways
- The declines are real and measured: total testosterone falls about 1.6% a year through middle age, growth hormone output about 14% per decade, and leg strength 3.4% to 4.1% a year in older men.
- Tesamorelin has the strongest data of any peptide here — an FDA-approved drug that cut visceral fat 15% in 26 weeks in a 412-patient trial that was 86% men.
- Retatrutide produced the largest weight change of anything on this page (−24% at 48 weeks), but a quarter to two-fifths of weight lost on this drug class is lean mass — the number a man over 50 has least to spare.
- Kisspeptin and PT-141 are the two peptides with trials in men for testosterone and sexual function; BPC-157, TB-500, MOTS-c and GHK-Cu are not tested in men over 50 for the things they’re sold for.
- Growth-hormone-axis compounds come with the same warnings the GH trials produced in older men: joint pain, fluid retention, carpal tunnel, and raised blood glucose.
What Changes in Men After 50
The reason this page exists is that the numbers move. In the Massachusetts Male Aging Study, which enrolled 1,709 men aged 40 to 70 and re-tested 1,156 of them seven to ten years later, total testosterone fell 1.6% a year and the bioavailable fraction 2–3% a year (study). In the Baltimore Longitudinal Study, about 20% of men over 60 tested in the hypogonadal range, 30% over 70, and 50% over 80 (study).
Growth hormone goes the same way. In healthy men aged 21 to 71, each decade cut daily GH output by about 14%, and each extra unit of BMI cut it another 6% (study). Deep sleep is part of why: the slow-wave share of the night drops from 18.9% at ages 16–25 to 3.4% at 36–50, and the GH pulse rides on that deep sleep (study). Strength goes faster than muscle: older men in the Health ABC cohort lost leg strength at 3.4% a year (white men; 4.1% for Black men), about three times the rate they lost leg muscle (study).

Peptides for Men Over 50 at a Glance
| Peptide | What men use it for | Human evidence for that use | Vial & list price |
|---|---|---|---|
| Tesamorelin | Belly fat, GH, recovery | Approved drug (HIV belly fat); older-adult cognition RCT | 10 mg · $69.99 |
| Sermorelin | GH, sleep, recovery | Small trials in men 64–76; formerly a prescription drug | 10 mg · $59.99 |
| CJC-1295 / Ipamorelin | GH pulse | Raises GH and IGF-1 in adults 21–61; no outcome trial | 10 mg · $59.99 |
| Retatrutide (GLP-3) | Weight, belly fat | Phase 2 RCT, 338 adults, 52% men | 10 mg · $69.99 |
| BPC-157 | Tendons, joints, gut | Uncontrolled knee series (17 patients, 16 followed up); animal data | 10 mg · $39.99 |
| TB-500 | Tendons, recovery | Parent peptide tested topically on leg ulcers; nothing injectable | 10 mg · $39.99 |
| Kisspeptin | Testosterone, libido | Small controlled trials in men, incl. 12-day dosing | 10 mg · $49.99 |
| PT-141 | Erections, desire | RCT in 342 men with ED; approved for women’s low desire | 10 mg · $29.99 |
| NAD+ | Energy, aging | Oral precursors tested in older men; injections untested | 500 mg · $69.99 |
| MOTS-c | Energy, metabolism | Mouse trials; no human trial | 10 mg · $39.99 |
| GHK-Cu | Skin, hair | Small skin studies | 50 mg · $29.99 |
| GLOW / KLOW | Skin, hair, repair | Component data only | 70 / 80 mg · $89.99 / $99.99 |
| Semax / Selank | Focus, mood | Russian trials in other conditions | 10 mg · $29.95 each |
| DSIP | Sleep | Two small insomnia trials, weak effect | 5 mg · $29.99 |
| Thymosin alpha-1 | Immune response | RCT in 90 men aged 65–99 (flu vaccine response) | 10 mg · $39.99 |

Muscle, Growth Hormone and Recovery
Tesamorelin is the one peptide on this page approved as a drug for something close to what men buy it for. Egrifta was approved in 2010 for excess abdominal fat in HIV patients, at a labelled dose of 2 mg injected daily (FDA). In the 412-patient trial behind it, 86% men, visceral fat fell 15.2% over 26 weeks while it rose 5% on placebo, triglycerides dropped 50 mg/dL, and IGF-1 rose 81% (study). The fat comes back quickly when you stop (study). It has also been given to 152 adults aged 55 to 87 for 20 weeks at 1 mg a day, with a favorable effect on cognition (study) — the largest controlled trial in older adults anything on this page has.
Sermorelin is the first 29 amino acids of GHRH — the same signal, shorter. It was sold as a prescription drug (Geref) and discontinued — not for safety or effectiveness reasons, according to FDA records. In eleven healthy men aged 64 to 76 with low IGF-1, 2 mg nightly for six weeks raised overnight GH release, though IGF-1 did not move and only two of six strength tests improved (study). In nineteen older adults, sixteen weeks of nightly dosing with a sermorelin analog roughly doubled overnight GH secretion in the men (study). Real signal, small trials, and no change in weight, BMI or DEXA muscle and fat.
CJC-1295 and ipamorelin are usually sold together. A single CJC-1295 injection raised GH two- to ten-fold for six days or more and IGF-1 1.5- to 3-fold for nine to eleven days in healthy adults aged 21 to 61 (study). Ipamorelin’s human data relevant here is pharmacokinetics — a two-hour half-life and one GH pulse per dose (study). Neither has a trial in older men measuring muscle, fat or strength. Our CJC/ipamorelin calculator handles the vial math.
The whole GH-axis idea rests on trials of growth hormone itself in healthy older people, and they are sobering. A 2007 systematic review (18 trial populations, mean age 69) found GH cut fat by 2.1 kg and added 2.1 kg of lean mass, with more swelling, joint pain, carpal tunnel and gynecomastia, and somewhat more new diabetes; the authors concluded GH “cannot be recommended as an antiaging therapy” (review). In a 131-person trial, men aged 65 to 88 gained 3.1 kg of lean mass but did not get measurably stronger, 41% developed joint pain versus none on placebo, and diabetes or glucose intolerance hit 18 GH-treated men versus 7 (study). Secretagogues raise your own GH instead of injecting it, and tesamorelin’s six-month trial showed only a fasting-glucose rise at two weeks that was gone by six months (study) — but its label carries the same warning list.
Belly Fat and Weight
Retatrutide (sold as GLP-3 by research vendors) is the drug with the biggest weight effect on this page. In the 48-week phase 2 trial — 338 adults, 52% of them men — body weight fell 8.7% at 1 mg a week, 17.1% at 4 mg, 22.8% at 8 mg and 24.2% at 12 mg, against 2.1% on placebo. Every participant on 8 or 12 mg lost at least 5% (study). In a DXA substudy of the type 2 diabetes trial, total fat mass fell 26.1% at 8 mg versus 4.5% on placebo (study). Side effects were gut-related and dose-dependent, and heart rate rose, peaking around week 24. For where the vials come from and what they cost: buy retatrutide online and the retatrutide calculator.
The caveat matters more at 50 than at 30. A 2026 meta-analysis of 20 randomized trials found that 25% to 39% of the weight lost on GLP-1-class drugs is lean mass — 35% for semaglutide, 25% for tirzepatide — which is about the same proportion as lifestyle programmes alone. The one arm that did better was lifestyle programmes built around resistance training, at 17.5% (meta-analysis). A man already losing muscle at 1% a year is the person that number was written for. The approved drugs in this class also have outcome data nothing else here has: in 17,604 heart patients, weekly semaglutide cut major cardiac events 20%, though 16.6% quit for side effects versus 8.2% on placebo (study).
Joints and Tendons
BPC-157 is what men over 50 buy for the shoulder that won’t heal, and the honest state of the evidence is: a pile of rat studies and one uncontrolled human series. In that series, a Florida clinic phoned 16 patients six to twelve months after injecting BPC-157 into a painful knee; 11 of 12 who got BPC-157 alone reported significant improvement. There was no control group and no validated outcome measure — patients rated their own pain by phone (study). The rest of the human data is a two-person IV safety pilot (a 58-year-old man and a 68-year-old woman) that found no changes in heart, liver, kidney, thyroid or glucose labs (study) and a 12-woman bladder-pain pilot (study). Our BPC-157 page and calculator cover the rest.
TB-500 is a synthetic fragment of thymosin beta-4, and the parent peptide has human trials — topical, on venous leg ulcers (study). Nobody has published a trial of injected TB-500 for tendons in people. The two are sold together as the Wolverine blend ($149.99 at list), and the same evidence applies to the blend as to its parts.
Testosterone, Libido and Erections
Kisspeptin is the hormone that tells the hypothalamus to release GnRH, which tells the pituitary to release LH, which tells the testes to make testosterone — and unlike most of this page, it has been tested in men. In six healthy men, a 90-minute infusion produced an average LH of 10.8 U/L versus 4.2 on saline, and testosterone of 24.9 versus 21.7 nmol/L (study). In four low-testosterone men with type 2 diabetes (mean age 34), an 11-hour infusion raised testosterone from 8.5 to 11.4 nmol/L (study). A 2026 study kept LH and testosterone up for 12 days with daily under-the-skin infusions (study), and in 32 men with low sexual desire a kisspeptin infusion raised penile response to erotic video by up to 56% over placebo (study). Those men averaged 38; nobody has run the trial in men over 50. More on kisspeptin for men and peptides for testosterone.
PT-141 (bremelanotide) works on the brain’s melanocortin receptors rather than on blood flow, which is why it was studied in men who didn’t respond to sildenafil. In 342 such men aged 28 to 59, a 10 mg nasal dose 45 minutes to two hours before sex produced a positive result in 33.5% versus 8.5% on placebo (study). Dose-finding work found erections starting about 30 minutes after nasal doses above 7 mg; flushing and nausea were the common side effects (study, study). The drug was approved in 2019 as Vyleesi — for low sexual desire in premenopausal women, not for men (FDA). See PT-141 for men.
Energy and Cellular Aging
NAD+ levels in tissue fall with age in men — the correlation is strong (study). Whether putting it back does anything has only been tested with oral precursors. In older men given 250 mg of NMN a day for six to twelve weeks, blood NAD+ rose and there were small improvements in gait speed and grip strength that the authors flagged as needing confirmation; body composition did not change (study). Nicotinamide riboside raised NAD+ in middle-aged and older adults over six weeks and was well tolerated (study). NAD+ by injection or nasal spray — what the research vendors sell — has no trial. Our NAD+ hub and injections page go deeper.
MOTS-c is a mitochondrial peptide that exercise raises naturally in humans and that, when injected into old mice, improved their physical capacity (study). There is no human interventional trial. What people actually inject and report is in the MOTS-c dosage report.
Skin and Hair
GHK-Cu is the copper peptide and the only skin compound here with human data — small data. In a 13-patient study of topical GHK-Cu after laser resurfacing, patients using it rated their skin quality higher, though objective measures showed no difference (study). It is most of what’s in the GLOW and KLOW blends, which men over 50 mostly buy for skin and for hair. The hair reports are user reports, not trials — the biggest KLOW hair thread we’ve logged this year is on r/tressless (thread). Details on the KLOW for hair page.
Brain, Sleep and Immune Function
Two Russian-developed peptides show up in men’s stacks, plus the sleep peptide DSIP and one thymic peptide. Semax raised BDNF and sped functional recovery in 110 stroke patients (mean age 58) in a Russian trial (study); there is no trial in healthy older men. Selank matched the benzodiazepine medazepam for anxiety in a 62-patient Russian trial (study). DSIP has two small insomnia trials from the 1980s and 90s; the authors of both judged the sleep improvement weak or of little clinical significance (study, study). Thymosin alpha-1 is the outlier: in a placebo-controlled trial of 90 men aged 65 to 99, twice-weekly injections alongside the flu shot improved antibody response (study). Our spray pages cover Semax, Selank and DSIP.

Peptides vs TRT
They answer different questions. Testosterone replacement replaces the hormone; the peptides above either nudge your own production (kisspeptin, and indirectly the GH secretagogues) or do something else entirely (fat loss, repair). The lab that sorts it out is LH and FSH alongside a morning testosterone. Low testosterone with high LH and FSH means the testes aren’t responding — primary hypogonadism, where signalling peptides have nothing to push on. Low testosterone with low or normal LH and FSH means the signal itself is weak — secondary hypogonadism, which is exactly the situation the kisspeptin trials in men with diabetes were probing (study). TRT has decades of outcome data; kisspeptin has infusions in a few dozen men. That is the honest comparison.
Safety After 50 and What to Test First
The risks on this page cluster in two places. Anything that raises GH and IGF-1 carries the list the older-adult GH trials produced — joint pain, fluid retention, carpal tunnel, raised glucose (review) — and tesamorelin’s own label adds a neoplasm warning and tells prescribers to monitor IGF-1 and glucose. The prostate question is real: in the Physicians’ Health Study, men in the top quartile of IGF-1 had 4.3 times the prostate cancer risk of the bottom quartile, independent of PSA (study). Anything in the GLP-1 class brings gut effects, a faster heart rate, and the lean-mass loss above.
The labs those trials checked before and during treatment are the sensible baseline: a morning total testosterone with LH and FSH, IGF-1, fasting glucose or HbA1c, a lipid panel, and a PSA. That’s not our recommendation; it’s what the researchers measured.
Over 40 vs Over 50
Same compounds, different starting point. In your 40s the numbers above are mid-decline and testosterone is usually still in range. Past 50 the trials start to include you — tesamorelin’s cognition trial averaged 68, one sermorelin trial enrolled men 64 to 76, the thymosin alpha-1 trial ran 65 to 99 — and so do their safety signals on glucose, joints and prostate. The men over 40 page covers the earlier decade.
Where to Buy and What It Costs
Every peptide on this page is stocked by Amino Club, the vendor we’ve ordered from and whose certificates we’ve read. Prices below are list; every single-compound vial we checked links to a lot-specific COA on its product page. These are sold for research use, not for human consumption.
Amino Club — up to 30% off your first order
Use code 15OFF at checkout. Lot-matched third-party COAs on the product pages. Research use only.
Frequently Asked Questions
Which peptide has the most evidence for men over 50?
Tesamorelin. It is an approved drug with a 412-patient trial (86% men) showing a 15% drop in visceral fat, and a 152-person trial in adults aged 55 to 87 showing a cognitive benefit. Nothing else on this page has a controlled trial of that size in this age group.
Do peptides raise testosterone?
Kisspeptin does, in the trials that exist: testosterone averaged 24.9 nmol/L versus 21.7 on saline after a 90-minute infusion in healthy men, and rose from 8.5 to 11.4 nmol/L in low-testosterone men with diabetes. Those are hours-long infusions in small groups; a 2026 study sustained the effect for 12 days. Growth-hormone peptides have not been shown to raise testosterone.
Are peptides safer than TRT?
Not in any way that has been measured. TRT has decades of outcome data; the peptides here have small short trials. Less data is not the same as safer. The GH-axis compounds in particular produced joint pain, fluid retention and raised glucose in older-adult trials.
Do growth hormone peptides cause prostate cancer?
No trial has shown that. What the data shows is that men with IGF-1 in the top quartile had 4.3 times the prostate cancer risk in the Physicians’ Health Study, and that GH secretagogues raise IGF-1 — tesamorelin by 81% in its main trial. Its label carries a neoplasm warning and tells prescribers to monitor IGF-1.
Will I lose muscle on retatrutide?
Some, almost certainly. Across 20 trials of this drug class, 25% to 39% of weight lost was lean mass. Lifestyle programmes that included resistance training lost only 17.5% as lean mass; nobody has measured that combination with retatrutide. The retatrutide DXA substudy described the lean-mass share of weight lost as similar to other obesity treatments, without giving a percentage in its abstract.
What does a vial cost?
At Amino Club list prices, single-compound vials run $29.95 (Semax, Selank) to $69.99 (tesamorelin, retatrutide, NAD+), with most 10 mg peptides at $39.99 to $59.99; the GLOW, KLOW and Wolverine blends run $89.99 to $149.99. How long a vial lasts depends entirely on the amount used, which is why we publish per-peptide dosage reports and calculators rather than a monthly figure.
The Bottom Line
For a man over 50 the list sorts itself by evidence fast. Tesamorelin and retatrutide have real trials with real body-composition numbers, and real trade-offs in glucose, joints and lean mass. Kisspeptin and PT-141 have small trials in men for exactly what men buy them for. Sermorelin has small trials in men your age showing it moves GH and not much else. Everything else — BPC-157, TB-500, MOTS-c, GHK-Cu, the blends, the sprays — runs on animal data, pilots and user reports. Buy from a vendor that shows the lot’s COA, get the labs the trials monitored, and treat every forum number as one man’s report.
Sources: PubMed IDs 11836290, 11158037, 1939523, 10938176, 17077199, 18057338, 20101189, 22869065, 25038357, 39325560, 9005976, 9360512, 16352683, 10496658, 17227934, 12425705, 37366315, 40609566, 41877354, 37952131, 34324435, 40131143, 20536470, 16174713, 23153270, 42549827, 36735255, 18206919, 14963471, 14999221, 22848760, 35927255, 29599478, 33473109, 16847171, 29798983, 18454096, 1299794, 3583493, 2642497, 9438850; FDA Drugs@FDA records BLA022505 (Egrifta), NDA019863/020443 (Geref), NDA210557 (Vyleesi). Vendor figures from Amino Club, checked September 18, 2026. Research use only; this page is not medical advice — see our medical disclaimer.